500 Boylston Street, 11th Floor
Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Our lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. We believe this product candidate has the potential to treat gastrointestinal conditions for which there are currently limited therapeutic options. We believe that ghrelin is a compelling target because of its critical role in regulating GI function and metabolism, and that peptide therapeutics are well suited for activating this target.
Founder: Bart Henderson
CEO: Keith M. Gottesdiener
CMO: Fred T. Fiedorek
Please click here for clinical trial information.